central composite design: blockedcube star) by evaluating the influence of the concentration of GMS,Lipoid(r) S100 and Nagch on the mean particle size and polydispersityindex (PDI) of the prepared samples. In order to stabilize SLNs againstaggregation in GIT, as well as to obtain local colon drug delivery,optimized formulation (sample 1) was further modified byincorporation of 5% Tween 20 (sample 2) and coated with EudragitO S100 in SLN/polymer ratio 1:10 (sample 3) by spray-drying (Buchi 290,Mini Spray Dryer, Swiss). CHARACTERIZATION OF BDS-SLNSThe particle size of BDS-SLNs was measured by Zetasizer Nano Series,Nano-ZS, Malvern Instruments Ltd., UK. The zeta potentialmeasurements were done after suspending the particles in buffersolutions (pH 2.0 and 7.4) of low molarities and ionic strength. In vitroGI stability was investigated by incubation of SLNs for 2 h in differentartificial GI fluids and mean particle size and surface charge weremeasured. Encapsulation efficiency (EE%) of BDS in SLNs wasdetermined by validated HPLC method.The drug release studies from SLNs were performed in buffer solutionsat pH 2.0 and 7.4 using the dialysis membrane. At specific time inter-vals aliquot of the dissolution medium were withdrawn and BDS in thesample solutions was analyzed by the HPLC. The in vitro release pat-terns were evaluated for linear curve fitting to zero order equation,first order equation, Higuchi's square root of time equation andWeibull model.RESULTS AND DISCUSSIONBy using 10% GMS, 1.4% Lipoid(r)S 100 and 0.4% NAgch (Fig.1, greypainted region), particles with an average diameter of 136 nm (PDI0.27) and unimodal narrow size distribution were prepared. Fig. 1. Response-surface graph showing optimal concentrations offormulation components by minimizing SLNs diameter and PIThere was no significant difference in particle size between un mo di -fi ed and Tween 20 modified formulations (Fig. 2). However, additionof non-ionic surfactant efficiently stabilized SLNs against aggregation/295Macedonian Pharmaceutical Bulletin 57 (suppl), 2011PHARMACEUTICAL TECHNOLOGY AND BIOPHARMACYposter presentationsFIFTH CONGRESS OF PHARMACY OF MACEDONIA WITH INTERNATIONAL PARTICIPATIONparticle growth in acidic pH. Zeta potential of Tween 20 stabilized particles measured in buffers atpH 2.0 and 7.4 was 0.5 and -18.8 mV, respectively, while drug EE was92.4% +- 1.85. Fig. 2. PDI of different SLNs loaded with BDSThe release profiles of BDS form designed formulations in buffersolutions at pH 2.0 and 7.4 are presented in Fig. 3. Fig. 3. Release profiles of BDS from different SLNs in buffers with pH2.0 and 7.4Eudragit coating has successfully sustained the release of BDS inbuffer solution at pH 2.0, while providing potential for efficient releaseof BDS at pH 7.4. The release rate was found to follow Higuchidiffusion model (r > 0.9988).CONCLUSIONPresented results confirm the potential of polymer coated SLNs asnovel drug carriers for local colon delivery of BDS via peroraladministration. REFERENCES1. Simonoska Crcarevska M, Glavas Dodov M, Goracinova K, Chitosan coated Ca-alginate microparticles loaded with budesonide for delivery to the inflamed colonicmucosa. Eur. J. Pharm. Biopharm. 2008; 68(3):565-578. 2. Serpe L, Canaparo R, et al. Solid lipid nanoparticles as anti-inflammatory drugdelivery system in a human inflammatory bowel disease whole-blood model. Eur. J.Pharm. Sci. 2010; 39:428-436.FORMULATsIJA NA SLN SOENKAPSULIRAN BUDEZONID ZANASOChENO I KONTROLIRANODELUVANjE VO KOLONOTKh. Litovin, K. Gorachinova, N. Geshkovski, M. S.Tsrtsarevska, S. Dimchevska, K. Mladenovska, M.Glavash DodovFarmatsevtski fakultet, Univerzitet "Sv. Kiril i Metodij",Vodnjanska 17, 1000 Skopje, MakedonijaVOVEDInflamatornite tsrevni zaboluvanja- IBD (ultserativen kolit iKronova bolest) se karakteriziraat so khronichna i nekontroliranainflamatsija na intestinalnata mukoza. Najchesto upotrebuvan lekza lokalen tretman na IBD e budezonidot (BDS), visoko potentenkortikosteroid so mala sistemska bioraspolozhivost i namalenrizik od pojava na nesakani efekti. Formuliranjeto nananopartikulirani sistemi kako nosachi na BDS za p.o. aplikatsijapretstavuva znachaen progres vo tretmanot na IBD, poradimozhnosta od postignuvanje na pogolema efikasnost i namaluvanjena nesakanite efekti preku efikasno nasochuvanje na lekot dotselnoto mesto na deluvanje (1). Tsvrstite lipidni nanochestichki (SLN) se vovedeni kakoalternativen sistem na traditsionalnite koloidni nosachi. SLN seizgradeni od tsvrst lipiden matriks, koj e biokompatibilen ibiorazgradliv, so mozhnost za nasocheno i kontroliranoosloboduvanje, pri shto se izbegnuva frekfentnoto doziranje, a sezgolemuva efikasnosta (2). Tsel na trudot beshe dizajniranje na SLN so vgraden BDS sodefinirani fizichko-khemiski i biofarmatsevtski karakteristikikoi kje ovozmozhat efikasen lokalen tretman na IBD po nivna p.o.aplikatsija. MATERIJALI I METODIMATERIJALIKako materijali bea koristeni: glitseril monostearat (GMSCutinaO, Cognis, Germany), fosfolipid (Lipoid S100O, Lipoid,Germany), natrium glikokholat (Nagch, New Zealand Pharm. Ltd),TweenO20 (Merck, Germany), budezonid (BDS, Crystal Pharma, Spain)i EudragitOS100 (Evonik, Germany). PODGOTOVKA NA SLN VO VGRADEN BDS SLN bea prigotveni so tekhnikata na rotor-stator toplakhomogenizatsija (Ultra-turraxO T18, Ika-Werke, Germany; vreme nakhomogenizatsija 7 min, 24.000 rpm). So primena na eksperimentalentsentralen kompoziten dizajn beshe sogledano vlijanieto naformulatsiskite varijabli: kontsentratsija na GMS, fosfolipid iNagch vrz srednata golemina na SLN i indeksot na po li di -sperznost (PDI). Optimalnata formulatsija beshe selektirana soprimena na response surface metodologijata. So tsel da se obezbedistabilnost na sistemot in vivo i da se suprimira osloboduvanjetona BDS vo gornite delovi na GIT, beshe naprevena povrshinskamodifikatsija na optimalnata formulatsija (primerok 1) prekuster na stabilizatsija so TweenO20 (primerok 2) i oblozhuvanje soEudragitO S100 (masen odnos polimer/SLN=10:1) (primerok 3), sotekhnikata na sprej-sushenje (Buchi 290, Mini Spray Dryer, Swiss). 296Makedonski farmatsevtski bilten 57 (dodatok), 2011FARMATsEVTSKA TEKhNOLOGIJA I BIOFARMATsIJAposter prezentatsiiPETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVOKARAKTERIZATsIJA NA SLN-BDS Goleminata na SLN i povrshinskata naelektriziranost beaopredeleni so primena na Zetasizer Nano Series(MalvernInstruments Ltd., UK). In vitro GI stabilnost beshe ispitana prekusledenje na promenata na goleminata na SLN po nivna inkubatsijavo simulirani GI puferi vo tek na 2 chasa. Efikasnosta naenkapsulatsija (EE%) na BDS vo SLN beshe opredelena so primenana validiran HPLC metod. Brzinata na osloboduvanje na BDS odpodgotvenite formulatsii beshe sledena vo disolutsioni mediumiso pH 2.0 i 7.4. Konstantite na brzina na osloboduvanje beapresmetani so koristenje na matematichkite modeli na kinetikiteod nulti i prv red, Higuchi-eva difuzija i Weibull-ov model. REZULTATI I DISKUSIJAOptimalnata formulatsija sostavena od 10% GMS, 1.4%fosfolipid i 0.4% Nagch rezultirashe so formiranje na SLN sosredna golemina od 136 nm i tesna unimodalna distributsija (PDI0.27) (Sl. 1. sivo oboen del). Ne beshe zabelezhana znachitelnarazlika vo goleminata na sterno oblozhenite i nativnite SLN.Slika 1. Response-surface dijagram: Prikaz na optimalnatakontsentratsija na sostavnite komponenti na formulatsijata prekuminimiziranje na sredniot dijametar i PDI.Oblozhuvanjeto so 5% TweenO20 obezbedi efikasna stabilizatsijana disperzijata na SLN vo kisela pH sredina. Zeta potentsijalot na sterno oblozhenite SLN vo puferi so pH 2.0i 7.4 iznesuvashe 0.5 i -18.8 mV, soodvetno, a EE iznesuvashe 92.4%.Brzinata na osloboduvanje na BDS od formulatsiite vo puferi sopH 2.0 i 7.4 e prikazhana na slika 3. Slika 3. Brzina na osloboduvanje na BDS od podgotvenite SLN vopuferi so pH 2.0 i 7.4Oblozhuvanjeto na SLN so eudrazhit rezultirashe so uspeshnosuprimiranje na osloboduvanjeto na BDS vo pufer so pH 2.0,dodeka vo pufer so pH 7.4 beshe postignato prodolzhenoosloboduvanje. Mekhanizmot na osloboduvanje najdobro mozhe da seopishe so Higuchi-eviot model na difuzja (r > 0.9988).ZAKLUChOKPrezentiranite rezultati go potvrdija potentsijalot na di zaj ni ra -n i te SLN kako nosachi na BDS za lokalen tretman vo kolonot ponivna peroralna administratsija. LITERATURA1. Simonoska Crcarevska M, Glavas Dodov M, Goracinova K, Chitosan coated Ca-alginate microparticles loaded with budesonide for delivery to the inflamed colonicmucosa. Eur. J. Pharm. Biopharm. 2008; 68(3):565-578. 2. Serpe L, Canaparo R, et al. Solid lipid nanoparticles as anti-inflammatory drugdelivery system in a human inflammatory bowel disease whole-blood model. Eur. J.Pharm. Sci. 2010; 39:428-436.CHARACTERIZATION OF SILICA XEROGELMICROPARTICLES AS 5-FU CARRIERS FORCOLON CANCER THERAPYB.Djurdjic1,2, N. Geskovski1, G. Petrusevski3, M. Si-monoska Crcarevska1, M. Glavas Dodov1, M.Cvetkovska4, K.Goracinova11Institute of Pharmaceutical technology, Faculty of Pharmacy, University Ss Cyril and Methodius, Skopje, Macedonia 2Faculty of Pharmacy, University of Montenegro, Podgorica, Montenegro3Research & Development, Alkaloid AD, Skopje, Macedonia4Faculty of Technology and Metallurgy, University Ss Cyril and Methodius, Skopje, Macedonia INTRODUCTIONIn resent years, selective drug delivery to the colon has been the focusof increasing scientific interest. Colon-targeted drug delivery systemsare designed to effectively protect drugs against premature degra da -tion, to localize drug moleculs at the targeted site of action and tocontrol the time and rate of drug release. Characteristics of sol-gelprocessed silica particles such as hydrophilicity, non-toxicity,biocompa tibillity, biodegradabillity, stability as well as possibilities ofeasy chemical and biochemical modification [1] make them favorablesystems-carriers for number of biologically active substances,especially in part of formulation of peroral dosage forms withcontrolled release in GIT. 5-FU is an antineoplastic agent and is thedrug of choice for treatment of colon cancer. Micro particulated car-rier systems for targeting od 5-FU to the colon would not only reducethe systemic toxicity of the drug but also allow an increase of the drugconcentration at the site of action [2]. The purpose of the presentstudy was to evaluate the suitability of silica xerogel microparticlesas carrier for site specific and controlled release of 5-FU.MATERIALS AND METHODS Materials: Silica xerogel microparticles (MPs) were prepared using thefollowing reagents: tetraethoxysilane (TEOS; Sigma, Germany), 3-aminopropyltriethoxysilane (APTES; Sigma, Germany), ethanol (Merck,Germany), acetic acid (Merck, Germany), 5-FU (EBEWE Pharma, Aus-tria) and deionised water.297Macedonian Pharmaceutical Bulletin 57 (suppl), 2011PHARMACEUTICAL TECHNOLOGY AND BIOPHARMACYposter presentationsFIFTH CONGRESS OF PHARMACY OF MACEDONIA WITH INTERNATIONAL PARTICIPATIONPreparation procedure: Silica xerogel MPs were prepared from TEOSbased silica sol (sample 1) and TEOS co- hydrolyzed with 1mol% (sam-ple 2) and 2.5mol% APTES (sample 3) at room temperature by using aone-step acid-catalized hydrolysis followed by spray drying of hy-drolyzed silica sol (Buchi 290, Mini Spray Dryer, Swiss). 5-FU was addedto the sol before spray drying at a concentration of 6 % (w/w). BlankMPs were also prepared.Characterization procedure: The morphology and surface appearanceof the prepared MPs were examined by scanning electron microscopy(Jeol-SEM 6400, Japan). The particle size distribution of MPs was meas-ured by laser difractometry using Mastersizer 2000 (Malvern In-strunents, UK). In order to determine 5-FU content in the MPs,predetermined amount of microparticles were dispersed in 1M NaOHunder continuous stirring at temperature not exceeding 60degC untilclear solution was obtained. 5-FU content in all prepared formulationwas determined by HPLC method (HPLC Agilent 1200 with UV detec-tor). Zeta potential of MPs in different buffers of low molarity and ionicstrength was measured using Zetasizer Nano Series, Malvern Instru-ments Ltd.,UK). The mucoadhesion was determined with modifiedeverted sac method [3].The FT-IR spectra of the prepared microparti-cles were collected using Varian 660 FT-IR spectrometer (KBr palletsmethod).In vitro release studies: The horizontal shaker method was used tostudy in vitro release profile of 5-FU from prepared formulations. MPswere suspended in 10 ml of phosphate buffer 7.4, to simulate ileo-colonconditions at appropriate intervals, samples (2ml) were withdrawn, fil-tered through 0.45 mm membrane filter and assayed by HPLC method.RESULTS AND DISCUSSIONSEM showed that the prepared MPs were spherical with smooth sur-faces as show in Fig.1. Particle size distribution of prepared samplesappeared as unimodal with median volume diameter 1.41mm (SPANfactor 1.15) and 1.94 mm (SPAN factor 1.10) and 1.95 mm (SPAN factor1.03) for sample 1, 2 and 3, respectively.